MX2012015188A - Composiciones de liberacion controlada con efecto de alimentos reducido. - Google Patents

Composiciones de liberacion controlada con efecto de alimentos reducido.

Info

Publication number
MX2012015188A
MX2012015188A MX2012015188A MX2012015188A MX2012015188A MX 2012015188 A MX2012015188 A MX 2012015188A MX 2012015188 A MX2012015188 A MX 2012015188A MX 2012015188 A MX2012015188 A MX 2012015188A MX 2012015188 A MX2012015188 A MX 2012015188A
Authority
MX
Mexico
Prior art keywords
controlled release
food effect
reduced food
release compositions
reduced
Prior art date
Application number
MX2012015188A
Other languages
English (en)
Spanish (es)
Inventor
Shou-Chiung Chen
Shao-Ming Lee
Chaur-Ming Jan
Original Assignee
Twi Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Twi Pharmaceuticals Inc filed Critical Twi Pharmaceuticals Inc
Publication of MX2012015188A publication Critical patent/MX2012015188A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2012015188A 2010-06-22 2011-06-21 Composiciones de liberacion controlada con efecto de alimentos reducido. MX2012015188A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35725110P 2010-06-22 2010-06-22
PCT/US2011/041218 WO2011163206A2 (en) 2010-06-22 2011-06-21 Controlled release compositions with reduced food effect

Publications (1)

Publication Number Publication Date
MX2012015188A true MX2012015188A (es) 2013-05-20

Family

ID=45328888

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012015188A MX2012015188A (es) 2010-06-22 2011-06-21 Composiciones de liberacion controlada con efecto de alimentos reducido.

Country Status (13)

Country Link
US (1) US8486453B2 (cg-RX-API-DMAC7.html)
EP (1) EP2585052A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013533241A (cg-RX-API-DMAC7.html)
KR (1) KR20140007247A (cg-RX-API-DMAC7.html)
CN (1) CN103037849A (cg-RX-API-DMAC7.html)
AR (1) AR084698A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011271124A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012032816A2 (cg-RX-API-DMAC7.html)
CA (1) CA2802335A1 (cg-RX-API-DMAC7.html)
MX (1) MX2012015188A (cg-RX-API-DMAC7.html)
RU (1) RU2012155890A (cg-RX-API-DMAC7.html)
TW (1) TW201206503A (cg-RX-API-DMAC7.html)
WO (1) WO2011163206A2 (cg-RX-API-DMAC7.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
JP5323684B2 (ja) 2006-05-04 2013-10-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 多形体
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US20110046076A1 (en) 2009-02-13 2011-02-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
KR20190071840A (ko) 2009-11-27 2019-06-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
MX366325B (es) 2010-05-05 2019-07-05 Boehringer Ingelheim Int Terapia de combinacion.
CA2803504C (en) 2010-06-24 2022-08-30 Boehringer Ingelheim International Gmbh A combination for diabetes therapy comprising linagliptin and a long-acting insulin
US20130251795A1 (en) * 2010-07-30 2013-09-26 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
UY33937A (es) * 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
KR101985384B1 (ko) 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
WO2013123595A1 (en) 2012-02-22 2013-08-29 Duchesnay Inc. Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
UY34856A (es) * 2012-07-03 2013-12-31 Bayer Pharma AG Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida
WO2014080383A1 (en) * 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Pharmaceutical composition of dipeptidyl peptidase-iv (dpp-iv) inhibitors in combination with other antidiabetics
US9452181B2 (en) 2013-07-22 2016-09-27 Duchesnay Inc. Composition for the management of nausea and vomiting
PL3024466T3 (pl) 2013-07-22 2018-08-31 Duchesnay Inc. Kompozycja do kontrolowania nudności i wymiotów
CN103655570B (zh) * 2013-12-11 2016-07-06 深圳翰宇药业股份有限公司 西格列汀与二甲双胍复方缓释制剂及其制备方法
CN104739835A (zh) * 2013-12-30 2015-07-01 中美华世通生物医药科技（武汉）有限公司 一种治疗糖尿病的新型药物组合物
WO2015101916A1 (en) 2013-12-30 2015-07-09 Mylan Laboratories Ltd. Process for the preparation of empagliflozin
KR101633292B1 (ko) * 2014-02-25 2016-06-24 동아에스티 주식회사 용법이 개선된 엔테카비어를 함유하는 약학적 조성물
WO2015130083A1 (ko) * 2014-02-25 2015-09-03 동아에스티 주식회사 용법이 개선된 엔테카비어를 함유하는 약학적 조성물
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
US10689460B2 (en) 2014-05-15 2020-06-23 Incube Labs, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
CA3198322A1 (en) 2014-05-15 2015-11-19 Rani Therapeutics, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
CN105287581A (zh) * 2014-07-15 2016-02-03 上海星泰医药科技有限公司 阿格列汀二甲双胍缓释片及其制备方法
TWI595874B (zh) 2014-08-29 2017-08-21 達契斯奈股份有限公司 多西拉敏及吡哆醇及／或其代謝產物或鹽之多模式釋放調配物
KR20180013880A (ko) * 2015-04-20 2018-02-07 티더블유아이 바이오테크놀로지 인코포레이티드 디아세레인을 함유하는 제제 및 이를 이용하여 요산의 혈중 농도를 감소시키는 방법
TWI684465B (zh) * 2015-04-22 2020-02-11 安成生物科技股份有限公司 含雙醋瑞因之製劑及使用其於降低尿酸血中濃度的方法
CN105055413A (zh) * 2015-07-23 2015-11-18 上海市第六人民医院 一种小檗碱和瑞格列奈的药物组合物
CN105496970A (zh) * 2015-12-18 2016-04-20 北京华禧联合科技发展有限公司 含有利格列汀的组合物及其制备方法
CN106924208A (zh) * 2015-12-30 2017-07-07 深圳翰宇药业股份有限公司 一种复方达格列净二甲双胍缓释片及其制备方法
WO2017153939A1 (en) * 2016-03-10 2017-09-14 Aurobindo Pharma Limited Pharmaceutical composition comprising canagliflozin, process of preparation and use thereof
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
JP2021521270A (ja) 2018-04-06 2021-08-26 アンマ セラピューティクス インコーポレイテッドＡｍｍａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 治療剤の制御放出用組成物
IT201800011119A1 (it) 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide per la somministrazione cronotropica di sitagliptin
TR201916829A2 (tr) * 2019-10-31 2021-05-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dapagli̇flozi̇n ve metformi̇n i̇çeren çi̇ft katmanli tablet formülasyonlari
CN110974792A (zh) * 2019-12-26 2020-04-10 南京亿华药业有限公司 一种结晶性药物片剂及其制备方法
WO2022073151A1 (en) * 2020-10-05 2022-04-14 Theracos Sub, Llc Pharmaceutical formulations
KR20250154775A (ko) * 2024-04-22 2025-10-29 제이피바이오 주식회사 다파글리플로진, 리나글립틴 및 메트포르민을 포함하는 안정성이 향상된 약제학적 제제

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6360257B1 (en) * 1998-01-30 2002-03-19 Telefonaktiebolaget L M Ericsson (Publ) Managing group IP addresses in mobile end stations
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
JP2005537298A (ja) * 2002-08-02 2005-12-08 ペンウェスト ファーマシューティカルズ カンパニー メトホルミンの徐放性製剤
EP2604266A1 (en) * 2002-09-20 2013-06-19 Andrx Labs Llc Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
WO2005009412A1 (en) * 2003-07-24 2005-02-03 Wockhardt Limited Oral compositions for treatment of diseases
CN1901881A (zh) * 2003-10-31 2007-01-24 阿尔扎公司 用于增强的吸收的组合物和剂型
JP2007509973A (ja) * 2003-10-31 2007-04-19 アルザ・コーポレーシヨン 増強された吸収のための組成物および投与形態物
WO2010045656A2 (en) * 2008-10-17 2010-04-22 Nectid, Inc. Novel sglt2 inhibitor dosage forms

Also Published As

Publication number Publication date
KR20140007247A (ko) 2014-01-17
CA2802335A1 (en) 2011-12-29
TW201206503A (en) 2012-02-16
BR112012032816A2 (pt) 2016-11-08
EP2585052A4 (en) 2014-10-01
AU2011271124A1 (en) 2013-01-10
AR084698A1 (es) 2013-06-05
RU2012155890A (ru) 2014-07-27
WO2011163206A3 (en) 2012-03-01
WO2011163206A4 (en) 2012-04-26
US8486453B2 (en) 2013-07-16
WO2011163206A2 (en) 2011-12-29
US20110311594A1 (en) 2011-12-22
EP2585052A2 (en) 2013-05-01
CN103037849A (zh) 2013-04-10
JP2013533241A (ja) 2013-08-22

Similar Documents

Publication Publication Date Title
MX2012015188A (es) Composiciones de liberacion controlada con efecto de alimentos reducido.
JOP20180102A1 (ar) مركب صيدلاني
HRP20181658T1 (hr) Kruti pripravci
EP2681268B8 (en) Organosiloxane compositions
IL233154A (en) Compounds, pharmaceuticals containing them and their uses
ZA201207093B (en) Solid compositions
EP2515682A4 (en) IN WATER DISPERSIBLE COMPOSITIONS FOR FOOD APPLICATIONS
EP2938325B8 (en) Diclofenac composition
EP2625231A4 (en) INK PRESERVATIVE COMPOSITIONS
GB201002861D0 (en) Compositions
MY165088A (en) Pharmaceutical compositions comprising alisporivir
ZA201209708B (en) Synergistic antioxidant composition
EP2588060A4 (en) BIOACTIVE COMPOSITIONS
ZA201403732B (en) An antimicrobial composition
GB201007790D0 (en) Compositions
GB201012359D0 (en) Invention 6.5.10
EP2866569B8 (en) Antimicrobial composition
GB201015621D0 (en) Invention 30.08.10
TN2013000218A1 (en) Pharmaceutical compositions comprising alisporivir
AU2012905697A0 (en) Improved antimicrobial composition
AU2012905670A0 (en) Improved antimicrobial composition
IL222808A0 (en) Synergistic antioxidant composition
AU2012904856A0 (en) Dental compositions
GB201002594D0 (en) Antimicrobial compositions
GB201111128D0 (en) Antimicrobial compositions

Legal Events

Date Code Title Description
FG Grant or registration